Retrospective study of brentuximab vedotin in combination with bendamustine in relapsed or refractory hodgkin lymphoma.

Trial Profile

Retrospective study of brentuximab vedotin in combination with bendamustine in relapsed or refractory hodgkin lymphoma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Dec 2017

At a glance

  • Drugs Bendamustine (Primary) ; Brentuximab vedotin (Primary)
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Dec 2017 New trial record
    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top